Realistic multi-cellular dosimetry for 177 Lu-labelled antibodies: model and application
| Autor: | Sara Marcatili, Riad Ladjohounlou, Helen Heyerdahl, Jostein Dahle, Alexandre Pichard, Isabelle Navarro-Teulon, A. Courteau, Manuel Bardiès, Jean-Pierre Pouget, Ada H. V. Repetto-Llamazares |
|---|---|
| Přispěvatelé: | Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM) |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Radiobiology
medicine.medical_treatment Monte Carlo method [SDV.CAN]Life Sciences [q-bio]/Cancer MESH: Monte Carlo Method 030218 nuclear medicine & medical imaging 03 medical and health sciences 3D cell culture MESH: Software 0302 clinical medicine MESH: Lymphoma Non-Hodgkin medicine Dosimetry Radiology Nuclear Medicine and imaging MESH: Tumor Cells Cultured MESH: Tissue Distribution Clonogenic assay Physics MESH: Humans Radiological and Ultrasound Technology business.industry MESH: Models Biological MESH: Radiometry 3. Good health Radiation therapy 030220 oncology & carcinogenesis Absorbed dose MESH: Antineoplastic Agents MESH: Rituximab Cellular model Biological system Nuclear medicine business MESH: Lutetium MESH: Radiopharmaceuticals [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| Zdroj: | Physics in Medicine and Biology Physics in Medicine and Biology, IOP Publishing, 2016, 61 (19), pp.6935-6952. ⟨10.1088/0031-9155/61/19/6935⟩ |
| ISSN: | 0031-9155 1361-6560 |
| DOI: | 10.1088/0031-9155/61/19/6935⟩ |
| Popis: | International audience; Current preclinical dosimetric models often fail to take account of the complex nature of absorbed dose distribution typical of in vitro clonogenic experiments in targeted radionuclide therapy. For this reason, clonogenic survival is often expressed as a function of added activity rather than the absorbed dose delivered to cells/cell nuclei. We designed a multi-cellular dosimetry model that takes into account the realistic distributions of cells in the Petri dish, for the establishment of survival curves as a function of the absorbed dose. General-purpose software tools were used for the generation of realistic, randomised 3D cell culture geometries based on experimentally determined parameters (cell size, cell density, cluster density, average cluster size, cell cumulated activity). A mixture of Monte Carlo and analytical approaches was implemented in order to achieve as accurate as possible results while reducing calculation time. The model was here applied to clonogenic survival experiments carried out to compare the efficacy of Betalutin®, a novel 177Lu-labelled antibody radionuclide conjugate for the treatment of non-Hodgkin lymphoma, to that of 177Lu-labelled CD20-specific (rituximab) and non-specific antibodies (Erbitux) on lymphocyte B cells. The 3D cellular model developed allowed a better understanding of the radiative and non-radiative processes associated with cellular death. Our approach is generic and can also be applied to other radiopharmaceuticals and cell distributions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|